Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

Abstract:
Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients with locally advanced head and neck cancers

· Biomarker analysis from soft tissue sarcoma clinical trial and new preclinical data supporting NBTXR3 mechanism of action in immune-oncology and its use in combination with immune checkpoint inhibitors

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018

Paris, France and Cambridge, MA | Posted on September 20th, 2018

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces it will present an update on and data from its NBTXR3 development program at the International Conference on Immunotherapy Radiotherapy Combinations that will take place from September 20 to 22, 2018 in Paris, France.



Follow-up of Phase I/II in advanced Head and Neck cancers in elderly and frail patients ineligible for cisplatin or intolerant to cetuximab

In the Phase I part of this trial, which is conducted to determinate the recommended dose, 18 patients have been injected with NBTXR3. Follow-up of patients that received highest doses of NBTXR3 (15% and 22% dose levels) shows that every patient alive at the 12-month cut-off date was still alive after 23 months or more. At 26 months, one of the patients treated at the 15% dose level had died.

These data suggest the potential of NBTXR3 to impact survival for this advanced cancer patient population.



Immuno biomarker study in randomized phase II/III soft tissue sarcoma clinical trial

Immunohistochemistry analyses revealed that, compared to radiation therapy alone (29 patients), NBTXR3 activated by radiation therapy (23 patients) increased the density of CD8+ T cell lymphocyte, and decreased FOXP3+ (Treg) into the tumors, while macrophage number remained relatively constant. These data indicate that NBTXR3 activated by radiation therapy could modulate the antitumor immune response.



In vivo investigation of NBTXR3 mode of action inducing distant immune response on CT26 tumoral model

Depletion experiment of CD8+ T cells (NBTXR3+3x4Gy+anti-CD8) induces a partial loss of tumor growth control of treated tumors, and a complete abolition of the abscopal effect (distal tumors). This result indicates that the abscopal effect was driven by CD8+ T cells. Interestingly, depletion of CD4+ T cells (NBTXR3+3x4Gy+anti-CD4) increases the efficacy of NBTXR3 + radiation therapy at both sites (treated and distal tumors). As anti-CD4 treatment lead to Treg depletion (known to have a protumoral role), Treg depletion might have improved NBTXR3 radiation therapy treatment. These observations continue to support the rationale for the use of NBTXR3 activated by radiation therapy to seek to transform tumors into an in situ cancer vaccine and its potential use in combination with immunotherapeutic agents.





International Conference on Immunotherapy Radiotherapy Combinations

September 20 to 22, 2018 - Paris, France

http://www.radio-immuno.siricsocrate.fr/en/ .



●●●



About NBTXR3

NBTXR3 is a first-in-class product designed to destroy, when activated by radiotherapy:

· tumors through physical cell death

· metastasis due to immunogenic cell death leading to activation of the immune system



NBTXR3 has a high degree of biocompatibility, requires one single administration before the whole radiotherapy treatment and Nanobiotix believes has the ability to fit into current worldwide standards of radiation care.



Nanobiotix’s broad clinical program includes 10 patient population evaluated in 7 clinical trials.

In June 2018, Nanobiotix established human proof of concept for this first-in-class product in its Soft tissue Sarcoma Phase III clinical trial.



NBTXR3 is actively being evaluated in head and neck cancer with locally advanced squamous cell carcinoma of the oral cavity or oropharynx in elderly and frail patients that are unable to receive chemotherapy or cetuximab with very limited therapeutic options. The Phase I/II trial has already delivered very promising results regarding the local control of the tumors.



Nanobiotix is running an Immuno-Oncology development program . In the United States., Nanobiotix has received the FDA’s approval to launch a clinical study of NBTXR3 activated by radiotherapy in combination with anti-PD1 antibodies in lung, and head and neck cancer patients (head and neck squamous cell carcinoma and non-small cell lung cancer).



The other ongoing NBTXR3 studies are treating patients with liver cancers (hepatocellular carcinoma and liver metastasis), locally advanced or unresectable rectal cancer in combination with chemotherapy, head and neck cancer in combination with concurrent chemotherapy, and prostate adenocarcinoma.



The first market authorization process (CE Marking) is ongoing in Europe in the soft tissue sarcoma indication.

####

About Nanobiotix
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.



The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.



Nanobiotix’s first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.



Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s Headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and european affiliates in Spain and Germany.

For more information, please click here

Contacts:
Nanobiotix



Sarah Gaubert

Director, Communication & Public Affairs

+33 (0)1 40 26 07 55

/









Noël Kurdi
Director, Investor Relations
+1 (646) 241-4400
/



Ricky Bhajun
Investor Relations Europe
+33 (0)1 79 97 29 99
/

Media relations





France - Springbok Consultants

Marina Rosoff

+33 (0)6 71 58 00 34







United States – RooneyPartners

Marion Janic

+1 (212) 223-4017

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

Nanomedicine

A*STAR, One BioMed launch S$9m joint lab to make diagnostic kit for infectious diseases December 3rd, 2018

New research could fine-tune the gene scissors CRISPR December 1st, 2018

It's not a shock: Better bandage promotes powerful healing November 29th, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

Announcements

Elliot Scientific now representing Raman Imaging specialists WITec in the UK and Eire - Unique correlative analysis in one instrument: Raman/AFM, Raman/SNOM December 10th, 2018

A new 'spin' on kagome lattices: Team's findings shed new light on the presence of spin-orbit coupling and topological spin textures in kagome lattices December 9th, 2018

Milestone for bERLinPro: Photocathodes with high quantum efficiency December 8th, 2018

Harnessing the power of 'spin orbit' coupling in silicon: Scaling up quantum computation December 7th, 2018

Events/Classes

CEA-Leti’s RRAM-based TCAM Circuits Meet Requirements of Multicore Neuromorphic Processors December 5th, 2018

CEA-Leti Moves 3D Sequential Integration Closer to Commercialization: Paper Presented at IEDM 2018 Describes Breakthroughs in Six Process Steps December 3rd, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

Bosch provides customized IoT and Industry 4.0 solutions: Bosch Mondeville and Bosch Connected Devices and Solutions collaborate to meet a wide variety of customer requirements November 16th, 2018

Nanobiotechnology

A*STAR, One BioMed launch S$9m joint lab to make diagnostic kit for infectious diseases December 3rd, 2018

New research could fine-tune the gene scissors CRISPR December 1st, 2018

Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results November 27th, 2018

How low can we go? Nanopore detection of single flu viruses to control outbreaks: Osaka University-led study shows that label-free digital diagnostics based on nanopore analytics and AI technology can characterize individual virions by their distinct physical features November 23rd, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project